MENACTRA
Drug
SANOFI PASTEUR INC.
Total Payments
$841,484
Transactions
28,920
Doctors
17,017
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $61.05 | 1 | 1 |
| 2023 | $119.61 | 7 | 7 |
| 2022 | $1,814 | 102 | 102 |
| 2021 | $7,981 | 266 | 260 |
| 2020 | $8,807 | 540 | 532 |
| 2019 | $45,357 | 2,154 | 2,016 |
| 2018 | $370,372 | 11,493 | 8,509 |
| 2017 | $406,972 | 14,357 | 10,801 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $471,740 | 28,436 | 56.1% |
| Consulting Fee | $149,459 | 39 | 17.8% |
| Unspecified | $146,825 | 242 | 17.4% |
| Travel and Lodging | $40,752 | 173 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,688 | 27 | 3.9% |
| Education | $20.74 | 3 | 0.0% |
Payments by Type
General
$694,659
28,678 transactions
Research
$146,825
242 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MET35: Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years | SANOFI PASTEUR INC. | $117,812 | 0 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age | SANOFI PASTEUR INC. | $23,140 | 0 |
| Immune Lot Consistency, lmmunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | SANOFI PASTEUR INC. | $2,990 | 0 |
| Efficacy, Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection | SANOFI PASTEUR INC. | $890.00 | 0 |
| Co-Administration of Menactra? (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) and Pentacel? (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate [Tetanus Toxoid Conjugate] Vaccine) at 15-18 Months of Age Has No Impact on Immune Responses | SANOFI PASTEUR INC. | $718.00 | 2 |
| Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra? Approximately Four Years Earlier | SANOFI PASTEUR INC. | $671.00 | 1 |
| Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) | SANOFI PASTEUR INC. | $604.00 | 1 |
Top Doctors Receiving Payments for MENACTRA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Theodore Bechrakis | — | Joliet, IL | $149,674 | 267 |
| , M.D | Pediatrics | St Petersburg, FL | $20,768 | 32 |
| , MD | Adolescent Medicine | Aurora, CO | $17,022 | 15 |
| , MD | Pediatrics | Louisville, KY | $16,164 | 17 |
| , M.D | Adolescent Medicine | Kansas City, MO | $15,643 | 14 |
| , M.D | Pediatrics | Los Angeles, CA | $12,332 | 20 |
| , MD | Pediatric Infectious Diseases | Syracuse, NY | $11,773 | 14 |
| , DO | Family Medicine | Glendale, AZ | $9,694 | 13 |
| , M.D | Pediatric Infectious Diseases | Corpus Christi, TX | $8,923 | 14 |
| , M.D | Pediatrics | Park Ridge, IL | $8,267 | 16 |
| , MD | Pediatrics | Houston, TX | $6,925 | 12 |
| , MD | Pediatrics | San Diego, CA | $6,778 | 7 |
| , MD | Infectious Disease | Baxter, TN | $6,763 | 5 |
| , MD MPH FAAP | Pediatric Infectious Diseases | Kansas City, MO | $6,678 | 5 |
| , MD PHD | Pediatrics | Aurora, CO | $6,673 | 15 |
| , MD | Family Medicine | Saint Paul, MN | $5,060 | 2 |
| , M.D | Infectious Disease | Omaha, NE | $4,980 | 9 |
| , DO | Pediatrics | Tulsa, OK | $4,948 | 9 |
| , MD | Pediatric Infectious Diseases | Chicago, IL | $4,307 | 3 |
| , M.D | Internal Medicine | Charlottesville, VA | $3,729 | 3 |
| , M.D | Internal Medicine | Rochester, MN | $3,409 | 1 |
| , DO PHD | Pediatric Hematology-Oncology | Des Moines, IA | $3,162 | 6 |
| , MD | Pediatric Infectious Diseases | New Haven, CT | $2,976 | 7 |
| , MD | Pediatric Infectious Diseases | Carmel, IN | $2,882 | 8 |
| , M.D | Family Medicine | Gold River, CA | $2,241 | 4 |
Ad
Manufacturing Companies
- SANOFI PASTEUR INC. $497,074
- Sanofi Pasteur Inc. $341,359
- VAXSERVE INC. $3,036
- SANOFI-AVENTIS U.S. LLC $15.00
Product Information
- Type Drug
- Total Payments $841,484
- Total Doctors 17,017
- Transactions 28,920
About MENACTRA
MENACTRA is a drug associated with $841,484 in payments to 17,017 healthcare providers, recorded across 28,920 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI PASTEUR INC..
Payment data is available from 2017 to 2024. In 2024, $61.05 was paid across 1 transactions to 1 doctors.
The most common payment nature for MENACTRA is "Food and Beverage" ($471,740, 56.1% of total).
MENACTRA is associated with 7 research studies, including "MET35: Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years" ($117,812).